about
On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug MonitoringPotential of Surface Enhanced Raman Spectroscopy (SERS) in Therapeutic Drug Monitoring (TDM). A Critical ReviewIndividualizing drug dosage with longitudinal data.Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.Induced urinary crystal formation as an analytical strategy for the prediction and monitoring of urolithiasis and other metabolism-related disorders.Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC-QToF-MS MethodDevelopment and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patientsFactors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient populationReview of evidence for measuring drug concentrations of first-line antitubercular agents in adults.A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children.Toward appropriate criteria in medication adherence assessment in older persons: Position Paper.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman.An Investigation of Liquid Chromatography-Mass Spectral Attributes and Analytical Performance Characteristics of Tenofovir, Emtricitabine and Efavirenz in Human Plasma.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.A Novel Chronic Opioid Monitoring Tool to Assess Prescription Drug Steady State Levels in Oral Fluid.Delivering precision antimicrobial therapy through closed-loop control systems.A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring.Bioanalytical methods for the detection of antidiabetic drugs: a review.Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region.Kinetic nomograms assist individualization of drug regimens.A novel statistical method for assessing effective adherence to medication and calculating optimal drug dosages.Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats.Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage.
P2860
Q27024074-EEB3A71C-B398-4853-B014-24542BA05C51Q28079197-F7659E0C-D3F2-49DD-A4BC-4D6B1A7036ECQ31108602-98B38FC7-5AEF-4F6A-A362-79D25E5205E5Q33784516-23023F83-3ABA-41D2-968A-25BF295491BBQ34114598-794CDE94-0EE4-4EA3-8A87-A3E1594DDED1Q36216123-E347B856-BAA9-4381-B7B9-94E5A205CB51Q36595204-E56B31D8-90B9-4311-821C-D0B5ABED0AA2Q37011672-AB4256E2-856E-403D-A21E-12A735C9743EQ37158873-50EF71B7-18AD-41EE-8C90-EDDCAE9EC865Q38244769-D60CD90A-18D7-4A00-B7AC-27CAD7CBDC05Q38547708-6FC17688-D70C-4BA9-8949-CF134180B9A2Q38657115-73F9CD93-4435-4AB9-8FEC-B1D4819CA827Q38775809-F6561355-92C4-4BFE-AFC7-A69809E231ACQ38954109-D8E3C767-8422-4CD1-803C-44B4E5CCC6A0Q38959281-C57721AC-F2D5-4076-AB05-4F04EBFD153BQ40278163-34CEDE4C-8B0F-4DF3-80CC-AD31183F211EQ40793702-68CC306F-C3DC-4CF7-B4AA-343421017765Q41092089-BD12A8DC-D5DD-46BD-9C61-E2C7C010A5A8Q42280851-F591CAF8-7C6A-4769-AEB8-75D6F927CDCCQ44339136-5789A29D-6FD2-425B-B33A-81DF198EFFAAQ47276911-84AE17EE-EEE7-4FA2-A501-42305E304FA1Q49221285-12521C21-A828-45B9-AC9B-7DE3E8776B2BQ49679474-2D21F6C6-05BA-49F6-8998-133F5E0B565EQ50040145-6F012E6F-ED84-4B46-807F-FD5F4A09C692Q51497219-38D0D4BD-E887-44CD-B88B-24D01B727D35Q52574413-08BB2163-B8B9-4C4C-AFFB-2077BC0E3C3CQ55030610-ECF3ED50-EE80-4E58-9B8A-B736DBAA143BQ55128082-0170A66D-AEBB-408B-AD5E-FC51DDAD475B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overview of therapeutic drug monitoring.
@en
Overview of therapeutic drug monitoring.
@nl
type
label
Overview of therapeutic drug monitoring.
@en
Overview of therapeutic drug monitoring.
@nl
prefLabel
Overview of therapeutic drug monitoring.
@en
Overview of therapeutic drug monitoring.
@nl
P2860
P356
P1476
Overview of therapeutic drug monitoring.
@en
P2093
Ju Seop Kang
Min Ho Lee
P2860
P356
10.3904/KJIM.2009.24.1.1
P577
2009-03-01T00:00:00Z